Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Neoadjuvant chemotherapy/neoadjuvant chemoradiotherapy (NAC/NACRT) can be performed in patients with pancreatic cancer to improve survival. We aimed to clarify the clinical outcomes of biliary drainage with a metal stent (MS) or a plastic stent (PS) during NAC/NACRT. Between October 2013 and April 2016, 96 patients with pancreatic cancer were registered for NAC/NACRT. Of these, 29 patients who underwent biliary drainage with MS or PS before NAC/NACRT and a subsequent pancreatoduodenectomy were retrospectively analyzed with regard to patient characteristics, preoperative recurrent biliary obstruction rate, NAC/NACRT delay or discontinuation rate, and operative characteristics. The median age of the patients was 67 years. NAC and NACRT were performed in 14 and 15 patients, respectively, and MS and PS were used in 17 and 12 patients, respectively. Recurrent biliary obstruction occurred in 6% and 83% of the patients in the MS and PS groups, respectively (p<0.001). NAC/NACRT delay was observed in 35% and 50% of the patients in the MS and PS groups, respectively (p=0.680). NAC/NACRT discontinuation was observed in 12% and 17% of the patients in the MS and PS groups, respectively (p=1.000). The operative time in the MS group tended to be longer than that in the PS group (625 minutes vs 497 minutes, p=0.051), and the operative blood loss volumes and postoperative adverse event rates were not different between the two groups. MS was better than PS from the viewpoint of preventing recurrent biliary obstruction, although MS was similar to PS with regards to perioperative outcomes.
Abstract
Neoadjuvant chemotherapy/neoadjuvant chemoradiotherapy (NAC/NACRT) can be performed in patients with pancreatic cancer to improve survival. We aimed to clarify the clinical outcomes of biliary drainage with a metal stent (MS) or a plastic stent (PS) during NAC/NACRT. Between October 2013 and April 2016, 96 patients with pancreatic cancer were registered for NAC/NACRT. Of these, 29 patients who underwent biliary drainage with MS or PS before NAC/NACRT and a subsequent pancreatoduodenectomy were retrospectively analyzed with regard to patient characteristics, preoperative recurrent biliary obstruction rate, NAC/NACRT delay or discontinuation rate, and operative characteristics. The median age of the patients was 67 years. NAC and NACRT were performed in 14 and 15 patients, respectively, and MS and PS were used in 17 and 12 patients, respectively. Recurrent biliary obstruction occurred in 6% and 83% of the patients in the MS and PS groups, respectively (p<0.001). NAC/NACRT delay was observed in 35% and 50% of the patients in the MS and PS groups, respectively (p=0.680). NAC/NACRT discontinuation was observed in 12% and 17% of the patients in the MS and PS groups, respectively (p=1.000). The operative time in the MS group tended to be longer than that in the PS group (625 minutes vs 497 minutes, p=0.051), and the operative blood loss volumes and postoperative adverse event rates were not different between the two groups. MS was better than PS from the viewpoint of preventing recurrent biliary obstruction, although MS was similar to PS with regards to perioperative outcomes.
참고문헌 (25)
- Scheufele F, "Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head : a meta-analysis of current literature", Surgery, 161, pp.939~950 (2017)
- Moole H, "Efficacy of preoperative biliary drainage in malignant obstructive jaundice : a meta-analysis and systematic review", World J Surg Oncol, 14, pp.182~ (2016)
- Lutz MP, "3rd St. Gallen EORTC Gastrointestinal Cancer Conference : consensus recommendations on controversial issues in the primary treatment of pancreatic cancer", Eur J Cancer, 79, pp.41~49 (2017)
- Tol JA, "Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer", Gut, 65, pp.1981~1987 (2016)
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- Heinrich S, "Neoadjuvant therapy of pancreatic cancer : definitions and benefits", Int J Mol Sci, 18, pp.E1622~ (2017)
- Almadi MA, "Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction : a series of meta-analyses", Am J Gastroenterol, 112, pp.260~273 (2017)
- Crippa S, "Systematic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectable periampullary or pancreatic head tumors", Eur J Surg Oncol, 42, pp.1278~1285 (2016)
- Isayama H, "TOKYO criteria 2014 for transpapillary biliary stenting", Dig Endosc, 27, pp.259~264 (2015)
- Cotton PB, "A lexicon for endoscopic adverse events : report of an ASGE workshop", Gastrointest Endosc, 71, pp.446~454 (2010)
- Katayama H, "Extended Clavien-Dindo classification of surgical complications : Japan Clinical Oncology Group postoperative complications criteria", Surg Today, 46, pp.668~685 (2016)
- Bassi C, "The 2016 update of the International Study Group(ISGPS)definition and grading of postoperative pancreatic fistula : 11 years after", Surgery, 161, pp.584~591 (2017)
- Moss AC, "Palliative biliary stents for obstructing pancreatic carcinoma", Cochrane Database Syst Rev, (2), pp.CD004200~ (2006)
- Sawas T, "Self-expandable metal stents versus plastic stents for malignant biliary obstruction : a meta-analysis", Gastrointest Endosc, 82, pp.256~267 (2015)
- Olsson G, "Preoperative biliary drainage by plastic or self-expandable metal stents in patients with periampullary tumors : results of a randomized clinical study", Endosc Int Open, 5, pp.E798~E808 (2017)
- Rose JB, "Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival", Ann Surg Oncol, 21, pp.1530~1537 (2014)
- Torgeson A, "Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins", ESMO Open, 3, pp.e000282~ (2018)
- Katz MHG, "Alliance for clinical trials in oncology(ALLIANCE)trial A021501 : preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas", BMC Cancer, 17, pp.505~ (2017)
- Tachezy M, "Sequential neoadjuvant chemoradiotherapy(CRT)followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma : NEOPA. A randomized multicenter phase III study(NCT01900327, DRKS00003893, ISRCTN82191749)", BMC Cancer, 14, pp.411~ (2014)
- Versteijne E, "Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer(PREOPANC trial) : study protocol for a multicentre randomized controlled trial", Trials, 17, pp.127~ (2016)
- Tsuboi T, "Preoperative biliary drainage in cases of borderline resectable pancreatic cancer treated with neoadjuvant chemotherapy and surgery", Gastroenterol Res Pract, 2016, pp.7968201~ (2016)
- Bethge N, "Human tissue responses to metal stents implanted in vivo for the palliation of malignant stenoses", Gastrointest Endosc, 43, pp.596~602 (1996)
- Euscher ED, "Histologic and immunohistochemical changes in the stented common bile duct", Appl Immunohistochem Mol Morphol, 15, pp.299~304 (2007)
- Pollom EL, "Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy", Semin Radiat Oncol, 27, pp.197~208 (2017)
- Maturen KE, "Imaging effects of radiation therapy in the abdomen and pelvis : evaluating"innocent bystander"tissues", Radiographics, 33, pp.599~619 (2013)